Literature DB >> 22406516

Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Megan B Wachsmann1, Laurentiu M Pop, Ellen S Vitetta.   

Abstract

With the continued failures of both early diagnosis and treatment options for pancreatic cancer, it is now time to comprehensively evaluate the role of the immune system on the development and progression of pancreatic cancer. It is important to develop strategies that harness the molecules and cells of the immune system to treat this disease. This review will focus primarily on the role of immune cells in the development and progression of pancreatic ductal adenocarcinoma and to evaluate what is known about the interaction of immune cells with the tumor microenvironment and their role in tumor growth and metastasis. We will conclude with a brief discussion of therapy for pancreatic cancer and the potential role for immunotherapy. We hypothesize that the role of the immune system in tumor development and progression is tissue specific. Our hope is that better understanding of this process will lead to better treatments for this devastating disease.

Entities:  

Mesh:

Year:  2012        PMID: 22406516      PMCID: PMC3319488          DOI: 10.2310/JIM.0b013e31824a4d79

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  311 in total

1.  PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells.

Authors:  P'ng Loke; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-15       Impact factor: 11.205

Review 2.  Soluble intercellular adhesion molecule-1 (sICAM-1): an overview.

Authors:  Anna Maria Witkowska; Maria Halina Borawska
Journal:  Eur Cytokine Netw       Date:  2004 Apr-Jun       Impact factor: 2.737

3.  Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer.

Authors:  Sean P Dineen; Christina L Roland; Rachel Greer; Juliet G Carbon; Jason E Toombs; Puja Gupta; Nabeel Bardeesy; Haizhou Sun; Noelle Williams; John D Minna; Rolf A Brekken
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

Review 4.  The dendritic cell-tumor cross-talk in cancer.

Authors:  Yuting Ma; Laetitia Aymeric; Clara Locher; Guido Kroemer; Laurence Zitvogel
Journal:  Curr Opin Immunol       Date:  2010-10-21       Impact factor: 7.486

5.  Oxidative stress and apoptosis.

Authors: 
Journal:  Pathophysiology       Date:  2000-09

6.  Immunological escape mechanisms in pancreatic carcinoma.

Authors:  H Ungefroren; M Voss; W V Bernstorff; A Schmid; B Kremer; H Kalthoff
Journal:  Ann N Y Acad Sci       Date:  1999-06-30       Impact factor: 5.691

7.  Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.

Authors:  S Soker; S Takashima; H Q Miao; G Neufeld; M Klagsbrun
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

Review 8.  Oncogenic stress sensed by the immune system: role of natural killer cell receptors.

Authors:  David H Raulet; Nadia Guerra
Journal:  Nat Rev Immunol       Date:  2009-08       Impact factor: 53.106

Review 9.  Fine tuning the immune response through B7-H3 and B7-H4.

Authors:  Kyung H Yi; Lieping Chen
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

10.  Mast cells can secrete vascular permeability factor/ vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of fc epsilon receptor I expression.

Authors:  J Boesiger; M Tsai; M Maurer; M Yamaguchi; L F Brown; K P Claffey; H F Dvorak; S J Galli
Journal:  J Exp Med       Date:  1998-09-21       Impact factor: 14.307

View more
  31 in total

1.  Development of Aggressive Pancreatic Ductal Adenocarcinomas Depends on Granulocyte Colony Stimulating Factor Secretion in Carcinoma Cells.

Authors:  Michael W Pickup; Philip Owens; Agnieszka E Gorska; Anna Chytil; Fei Ye; Chanjuan Shi; Valerie M Weaver; Raghu Kalluri; Harold L Moses; Sergey V Novitskiy
Journal:  Cancer Immunol Res       Date:  2017-08-03       Impact factor: 11.151

Review 2.  Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma.

Authors:  Lei Zheng; Jing Xue; Elizabeth M Jaffee; Aida Habtezion
Journal:  Gastroenterology       Date:  2013-06       Impact factor: 22.682

3.  4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer.

Authors:  Donastas Sakellariou-Thompson; Marie-Andrée Forget; Caitlin Creasy; Vincent Bernard; Li Zhao; Young Uk Kim; Mark W Hurd; Naohiro Uraoka; Edwin Roger Parra; Ya'an Kang; Christopher A Bristow; Jaime Rodriguez-Canales; Jason B Fleming; Gauri Varadhachary; Milind Javle; Michael J Overman; Hector A Alvarez; Timothy P Heffernan; Jianhua Zhang; Patrick Hwu; Anirban Maitra; Cara Haymaker; Chantale Bernatchez
Journal:  Clin Cancer Res       Date:  2017-09-25       Impact factor: 12.531

Review 4.  Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.

Authors:  Clara S Mundry; Kirsten C Eberle; Pankaj K Singh; Michael A Hollingsworth; Kamiya Mehla
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-06-21       Impact factor: 10.680

Review 5.  Phosphatidylinositol 3-Kinase: A Link Between Inflammation and Pancreatic Cancer.

Authors:  Chiara Birtolo; Vay Liang W Go; Andrzej Ptasznik; Guido Eibl; Stephen J Pandol
Journal:  Pancreas       Date:  2016-01       Impact factor: 3.327

Review 6.  Mechanistic insights into self-reinforcing processes driving abnormal histogenesis during the development of pancreatic cancer.

Authors:  Juan L Iovanna; David L Marks; Martin E Fernandez-Zapico; Raul Urrutia
Journal:  Am J Pathol       Date:  2013-01-31       Impact factor: 4.307

Review 7.  Macrophages and pancreatic ductal adenocarcinoma.

Authors:  Aida Habtezion; Mouad Edderkaoui; Stephen J Pandol
Journal:  Cancer Lett       Date:  2015-12-18       Impact factor: 8.679

8.  The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells.

Authors:  Philip J Vernon; Tara J Loux; Nicole E Schapiro; Rui Kang; Ravi Muthuswamy; Pawel Kalinski; Daolin Tang; Michael T Lotze; Herbert J Zeh
Journal:  J Immunol       Date:  2012-12-26       Impact factor: 5.422

9.  Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.

Authors:  Keisuke Watanabe; Yanping Luo; Tong Da; Sonia Guedan; Marco Ruella; John Scholler; Brian Keith; Regina M Young; Boris Engels; Suvi Sorsa; Mikko Siurala; Riikka Havunen; Siri Tähtinen; Akseli Hemminki; Carl H June
Journal:  JCI Insight       Date:  2018-04-05

10.  A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.

Authors:  Friedrich H Schmitz-Winnenthal; Nicolas Hohmann; Thomas Schmidt; Lilli Podola; Tobias Friedrich; Heinz Lubenau; Marco Springer; Sébastien Wieckowski; Klaus M Breiner; Gerd Mikus; Markus W Büchler; Anne-Valerie Keller; Ruhan Koc; Christoph Springfeld; Phillip Knebel; Mariana Bucur; Lars Grenacher; Walter E Haefeli; Philipp Beckhove
Journal:  Oncoimmunology       Date:  2018-01-16       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.